Search
NEWS

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

By A Mystery Man Writer

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

IJMS, Free Full-Text

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

A senescent vascular profile in human irreversible PAH-CHD

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

Laszlo FARKAS, Associate Professor, The Ohio State University, OH, OSU, Division of Pulmonary, Allergy, Critical Care & Sleep Medicine

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

A p53-TLR3 axis ameliorates pulmonary hypertension by inducing

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

Immunofluorescent MAP2 staining of human neuronal cells treated

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

PDF) IL-32 Promotes Angiogenesis

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

Bas Heinhuis's research works Radboud University Medical Centre (Radboudumc), Nijmegen and other places

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

PDF) IL-32 Promotes Angiogenesis

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

Charles DINARELLO, University of Colorado, CO, UCD, Division of Infectious Diseases

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

miR‑371b‑5p inhibits endothelial cell apoptosis in monocrotaline

IL-32 in PAH. ( A – D ) Triple-label immunofluorescence images of human

Tania AZAM, University of Colorado, CO, UCD, Division of Infectious Diseases